Research Specialist

Department of Pathology and Laboratory Medicine
6105 Neurosciences Building


ryan_bash [at]




University of North Carolina School of Medicine

Masters of Science (MS), June 2010

 Curriculum in Genetics and Molecular Biology

University of North Carolina

Bachelor of Science, December 2000

Major:  Biology


  1. McNeill RS, Stroobant EE, Smithberger E, Canoutas DA, Butler MK, Shelton AK, Patel SD, Limas JC, Skinner KR, Bash RE, Schmid RSMiller CR.  PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.  PLoS One.  13(7):e0200014 Jul 2018.  PMID: 29975751  PMCID: PMC6033446
  2. Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR.  MerTK as a therapeutic target in glioblastoma.  Neuro-oncology. 20(1):92-102 Jan 2018.  PMID: 28605477  PMCID:  PMC5761530
  3. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.  Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.  Neuro-oncology.  19(11):1481-1493 Oct 2017.  PMID: 28486691  PMCID:  PMC5737524
  4. McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.  Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.  Neuro-oncology.  19(11):1469-1480 Oct 2017.  PMID: 28379424  PMCID:  PMC5737415
  5. Vitucci M*, Irvin DM*, McNeill RS, Schmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AM, Bash RE, Kim S, Berens ME, Miller CR.  Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.  Neuro-oncology.  19(9):1237-1247 Sep 2017.  *Co-first authors.  PMID: 28398584  PMCID:  PMC5570221
  6. Schmid RS, Simon JM, Vitucci M, McNeill RS, Bash RE, Werneke AM, Huey L, White KK, Ewend MG, Wu J, Miller CR.  Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation, but resistant to temozolomide.  Neuro-oncology.  18(7):962-973 Jul 2016.  PMID: 26826202  PMCID: PMC4896545
  7. Okolie O, Bago JR, Schmid RS, Irvin DM, Bash RE, Miller CR*, Hingtgen SD*.  Reactive astrocytes potentiate tumor aggressiveness in murine glioma resection and recurrence model.  Neuro-oncology.  DOI: 10.1093/neuonc/now117 Jun 2016.  PMID: 27298311  *Co-senior authors.
  8. Irvin DM, McNeill RS, Bash RE, Miller CR.  Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models.  Brain Pathology.  Epub Jan 13, 2016.  DOI: 10.1111/bpa.12348.  PMID: 26762242
  9. Karginova O, Siegel MB, Adamo B, Deal AM, Van Swearingen AED, Nikolaishvili-Feinberg N, Parker JS, Santos CM, Darr D, Bash R, Sandison K, Zamboni WC, Miller CR, Anders CK.  Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast cancer.  Molecular Cancer Therapeutics.  14(4):920-930 Apr 2015. PMID: 25824335  PMCID: PMC4394032
  10. McNeill RS, Schmid RS, Bash RE, Vitucci M, White KK, Werneke AM, Constance BH, Huff B, Miller CR.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.  Journal of Visualized Experiments.  90:e51763 Aug 2014.  PMID: 25146643.
  11. Song Y, Zhang Q, Kutlu B, Difilippantonio S, Bash R, Gilbert D, Yin C, O’Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN, Miller CR, Hood L, Van Dyke T.  Evolutionary etiology of high-grade astrocytomas.  Proceedings of the National Academy of Science USA.  110(44):17933-17938 Oct 2013.  PMID: 24114272 PMCID: PMC3816471
  12. Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR.  Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.  Neuro-oncology.  15(10):1317-1329 Oct 2013.  PMID: 23814263  PMCID: PMC3779038
  13. Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Walsh M, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC.  Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.  PLoS One.  8(5): e61359 May 2013.  PMID: 23650496  PMCID: PMC3641071
  14. Simin K, Hill R, Song Y, Zhang Q, Bash R, Cardiff RD, Yin C, Xiao A, McCarthy K, van Dyke T.  Deciphering cancer complexities in genetically engineered mice.  Cold Spring Harb Symp Quant Biol.  70:283-290.  2005.  PMID: 16869764
  15. Bash R, Matthysse AG.  Attachment of roots and virulence of a chvB mutant of Agrobacterium tumefaciens are temperature sensitive.  Mol Plant Microbe Interact.  15(2):160-163.  Feb 2002.  PMID: 11876426